

The Smarter Way to Forecast Pharma Markets

Empower your team with
intuitive, best-practice
forecasting tools designed
for pharmaceutical success.

Cancer Type: Multiple Myeloma Transplant Eligible Details: Stage: I,II,III, Line I											
	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Incident Patients	34,560,000	35,251,200	35,956,224	36,675,348	37,408,855	38,157,033	38,920,173	39,697,577	40,488,548	41,293,390	42,112,126
Diagnosis rate	13 %	12 %	14 %	16 %	17 %	20 %	22 %	21 %	20 %	22 %	20 %
Diagnosed patients	4,492,800	4,230,144	5,033,871	5,868,056	6,359,505	7,631,407	8,552,438	8,336,701	8,098,500	9,067,528	8,425,125
Treatment Rate	45 %	47 %	49 %	51 %	52 %	54 %	55 %	55 %	56 %	58 %	59 %
Treated patients	2,021,760	1,988,168	2,466,597	2,992,708	3,306,943	4,120,960	4,709,341	4,585,186	4,535,165	5,270,186	4,971,125

Trending											
Name	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Treated patients	2,021,760	1,988,168	2,466,597	2,992,708	3,306,943	4,120,960	4,709,341	4,585,186	4,535,165	5,270,186	4,971,125

Historical Market Shares (share of Treated patients)											
Name	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Beclometasone	13 %	15 %									
Fluticasone	4 %	2 %									
Serevent	19 %	17 %									
Foreadil	8 %	10 %									
Striverdo	22 %	20 %									
Symbicort	10 %	12 %									

A More Precise Approach To Forecasting With Onco+


Advanced forecasting software that redefines industry standards.

Generate more accurate and actionable insights for any market, disease area, or product. Part of the FC+ suite of Excel add-ins, Onco+ is purpose-built for oncology forecasting and patient segmentation. It combines best-practice methodology with intuitive design to quickly build transparent and robust models for analyzing cancer markets and optimizing strategic decisions.

**CREATE SOPHISTICATED
PATIENT FLOW FORECASTS
FOR ALL ONCOLOGY DISEASES
- EFFICIENTLY AND COST-
EFFECTIVELY.**

Why Choose Onco+

- ▶ Tailored specifically for key oncology challenges
- ▶ Create multiple forecasts efficiently
- ▶ Follow patients through their treatment pathway
- ▶ All complex algorithms built in
- ▶ Training and support included
- ▶ Easy to use for all teams



FC+

Evaluate
a norstell company

J+D
an Evaluate company

Onco+ transforms complex data into actionable insights, empowering teams to forecast with greater accuracy and confidence.

SimScore

Estimate peak share by comparing product profiles

Monte Carlo Risk Analysis

Understand the impact of uncertainty and probability in your forecasts

Data Phaser

Instantly phase annual forecasts into monthly or quarterly views for sharper, more flexible insights

Efficiency and Consolidation

Instantly aggregate scenarios, indications, or regional forecasts for a complete view

EXCEL ADD-IN FOR ONCOLOGY FORECASTING,
BUILT ON DECADES OF INDUSTRY EXPERTISE.

Intuitive, Agile, Engaging, Innovative

EXPERIENCE
ONCO+ TODAY

[Book a demo](#)



Responsive and user-friendly
Excel-based application



Modular approach: add to existing
models or build from scratch



Risk analysis, peak share
predictor, demand analysis



Visualize data in a click



Efficient, cost-effective, and flexible

The FC+ Suite

EPI+

SALES+

ONCO+

FLOW+

Each module is designed to meet specific forecasting needs, from trend-based sales forecasts to complex patient flow models.

Ready to transform your
pharmaceutical forecasting?
[Get in touch](#) to find out how we can help.

Evaluate
a norstella company

J+D
an Evaluate company

info@evaluate.com | www.evaluate.com

Evaluate HQ: +44-(0)20-7377-0800 | Evaluate Americas: +1-617-573-9450 | Evaluate APAC: +81-(0)80-1164-4754